Fomes fomentarius

Fomes fomentarius (Tinder Fungus / Hoof Fungus): A Comprehensive Reference

1. Identity, Taxonomy, and Natural Source

Fomes fomentarius is a species of basidiomycete fungi in the family Polyporaceae (bracket fungi). It is a medicinal polypore mushroom, commonly known as the tinder fungus, belonging to the family Polyporaceae, and is a parasitic-saprophytic fungus playing a crucial role in forest decomposition and nutrient cycling. The species was formally described by the Swedish mycologist Elias Magnus Fries, carrying the full binomial authority Fomes fomentarius (L.) Fr. It is also referenced under earlier synonyms including Boletus fomentarius L. and Pyropolyporus fomentarius.

Common names include the tinder fungus, hoof fungus, tinder conk, tinder polypore, and Iceman fungus. The woody fruiting body is often shaped like a horse's hoof, hence one of its common names, "hoof fungus," and the species also goes by the names tinder conk, tinder fungus, tinder polypore, and Iceman fungus.

Fomes fomentarius is a lignivorous mushroom that normally grows on oaks, birch, or beech trees, acting as a decomposer and a parasite producing white-mottled rot, and is widely distributed throughout Europe, Asia, Africa, and North America. More specifically, it is widely distributed across the Northern Hemisphere, typically growing on hardwood trees such as beech, birch, and oak.

It forms high-size and hoof-shaped fruiting bodies, and, because of their tough anatomy and woody structure, F. fomentarius is considered edible but non-palatable, so it is not usually consumed as food. It has no stem or stipe, nor does it have gills, but instead has a flat lower surface covered with pores, which are the openings of densely-packed, spore-producing tubes.

Common Forms and Preparations

The high mineral content of F. fomentarius further validates its potential as a source of bioactive compounds and food supplements, particularly for mitigating mineral deficiencies and promoting bone health. However, its hard texture makes it unsuitable for direct consumption, necessitating its use in processed forms such as extracts or supplements.

Preparations documented in the scientific literature include:

• Water (hot aqueous) extracts: Prepared by boiling dried, powdered fruiting body material. The dried F. fomentarius is homogenized to a fine powder; one preparation method boils 100 grams of powdered material in water (1:10 wt/vol) for 4 hours.
• Ethanolic / hydroethanolic extracts: Lyophilized and ground fruiting body powder has been extracted into 70% ethanol on a shaking incubator, then filtered and freeze-dried.
• Insoluble fiber preparations (amadou): The feltlike, spongy inner layer of the fruiting body — known as amadou — can be processed into wound dressings and fiber-based dietary supplements.
• Melanin-glucan and chitin-glucan complexes: Specific biopolymer fractions isolated from the fruiting body and studied for wound care and anti-infective applications.
• Dietary supplement (Good Feeling Power®): A dietary supplement from the fruiting bodies of the mushroom Fomes fomentarius (Good Feeling Power®) has been tested in the context of Crohn's disease due to its immunomodulatory activity on the innate as well as adaptive immune functions.
• Isolated compound fractions: Polysaccharides, sterols (fomentarols), and the pigment fomentariol have been isolated via preparative HPLC and other chromatographic methods for research purposes.

2. Traditional and Historical Use

Prehistoric and Archaeological Evidence

Fomes fomentarius (tinder fungus or hoof fungus) has a longstanding role in traditional medicine and various practical applications, and is one of the earliest documented medicinal mushrooms, used for fire-starting, preservation, first aid, insect repellents, and spiritual rituals.

Fomes fomentarius was found with the 5,000-year-old Iceman (Ötzi) who may have used this polypore to make and preserve fire, as a first-aid kit, as an insect repellent, or for spiritual purposes. Prehistoric artefacts going back to over 5,000 years underline the long tradition of using polypores for various applications ranging from food or tinder material to medicinal and spiritual uses, as witnessed by two polypore species found among items of Ötzi, the Iceman. The use of F. fomentarius by human populations may extend even further back: remains attributed to this species have been identified at the Mesolithic site of Star Carr in England, dated to approximately 7,600 BCE.

European Folk and Medical Traditions

Fomes fomentarius was widely used as a styptic by surgeons, barbers, and dentists, and was therefore called "agaric of the surgeons." Furthermore, in European, West Siberian, and Indian folk medicine, a kind of absorbing dressing made of tinder and some iodine was externally applied to wounds and burns.

In the German-speaking Alpine area, Fomes fomentarius was called "Wundschwamm" or "Chirurgenschwamm" and was sold in pharmacies in the form of styptic bandages. This absorbing wound tissue was used by Austrian farmers up to the 19th century. Moreover, around Easter, Fomes fomentarius fruiting bodies were used for ritual smoking ceremonies in Germany and Austria.

Fruiting bodies were employed in ceremonial smoking rituals in Germany and Austria and in West Siberia, where the Khanty burned them to ward off the influence of the deceased.

In Germany, Hungary, and in some parts of former Yugoslavia, Fomes fomentarius was used for making caps, chest protectors, and other clothing articles. In Germany and former Bohemia, large fruiting bodies were often used for decorative purposes such as flower pots. In fly fishing, pads of "amadou" were used as an excellent absorbent for drying water-logged fishing flies.

In Transylvania, part of Romania, fungi are traditionally used in human medicine, handicraft, and various customs for a long time. The ethnomycological use of the tinder fungus starts with the traditional steps of collection, storage, trimming, and involves use for ethnomedicinal purposes and preparation of unique handmade products, which are still available on national and international markets.

Fomes fomentarius has been valued since at least the 15th century across Europe, including the Balkan region, for its medicinal and traditional uses such as tinder production, spiritual practices, wound healing, and hemostasis.

Asian Traditional Medical Systems

F. fomentarius, a basidiomycete fungus, has been used as a traditional Chinese and Korean medicine for many centuries for the treatment of various diseases, including oral ulcers, gastroenteric disorders, hepatocirrhosis, inflammation, and various cancers.

Fomes fomentarius has also been employed in traditional Chinese medicine to treat rheumatism, painful menstruation (dysmenorrhea), hemorrhoids, and bladder problems, and mushrooms of this species have been utilized in treating malignant tumors of the uterus, stomach, and esophagus.

The ancient Greek physician Hippocrates is cited in secondary ethnomycological sources as having noted the anti-inflammatory properties of Fomes fomentarius around 450 BCE. Although this mushroom is described in sources dating to the 5th century BC and has been traditionally used worldwide for different purposes, relatively little has been published about the details of its medicinal usage until recently.

3. Key Constituents and Active Compounds

The bioactive composition of F. fomentarius includes phenolic compounds, polysaccharides (e.g., β-glucans), proteins, sterols, terpenes, terpenoids, betulin and betulinic acid. Recent research has highlighted its rich mycochemical composition, including phenolics, benzofurans, coumarins, triterpenoids, and polysaccharides like β-glucans.

Phenolic Compounds

Liquid chromatography-mass spectrometry (LC-MS) analysis of Moroccan F. fomentarius identified 24 phenolic compounds, with isorhamnetin (2,734.00 µg/g), p-hydroxybenzoic acid (409.00 µg/g), and kaempferol (351.10 µg/g) as the most abundant. Spectrophotometric analysis showed high levels of total phenolics (75.83 mg GAE/g dry matter equivalent) and flavonoids (37.62 mg CE/g dry matter equivalent), and GC–MS analysis identified 109 volatile and non-volatile compounds, primarily sugars (24), fatty acids (23), alcohols (10), organic acids (9), and terpenoids (6).

Fomentariol

The brown-red colour of the external layer of Fomes fomentarius is essentially due to three compounds. The main constituent, fomentariol, has the structure 7,4′-di(3-hydroxy-1-propenyl)-purpurogallin and represents a novel benzotropolone. Fomentariol is a constituent of Fomes fomentarius considered responsible for its antidiabetic potential.

Fomentarols (Sterols)

Four novel steroidal compounds named Fomentarols A–D were isolated from F. fomentarius fruiting bodies and reported by Zang et al. (2013) in Phytochemistry. Zang Y. and colleagues isolated fomentarols A–D, sterols from the polypore macrofungus Fomes fomentarius, publishing their findings in Phytochemistry in 2013 (volume 92, pages 137–145).

Polysaccharides and β-Glucans

Among the bioactive compounds of mushrooms, polysaccharides are the most well-known and most potent mushroom-derived substances with anti-tumor activity. A chemically water-extractable polysaccharide (designated MFKF-AP1β), with a molecular weight of 12 kDa, has been isolated from fruiting bodies of Fomes fomentarius. The exopolysaccharide (EPS) of F. fomentarius has β-D-glucan chains.

Methyl 9-Oxo-(10E,12E)-octadecadienoate

Methyl 9-Oxo-(10E,12E)-octadecadienoate, a fatty acid ester isolated from Fomes fomentarius, attenuates lipopolysaccharide-induced inflammatory response by blocking phosphorylation of STAT3 in murine macrophages, as published in Mycobiology in 2015 (volume 43, issue 3, pages 319–326).

Betulin and Betulinic Acid

HPLC data from studies of F. fomentarius ethanol extract confirmed it contains betulin, and several studies have reported that betulin from Fomes fomentarius has cytotoxic effects against cancer cells.

Chitin, Melanin, and Structural Biopolymers

The cell wall and structural layers of F. fomentarius fruiting bodies contain significant amounts of chitin, β-glucan, and melanin. These biopolymers — particularly the chitin-glucan-melanin complex — have been the subject of applied research for hemostatic and wound-care applications.

4. Mechanisms of Action

Antioxidant

The phenolic and polysaccharide compounds of F. fomentarius are linked to the mushroom's antiproliferative and antioxidant activities, with specific polyphenols and triterpenoids playing crucial roles in modulating oxidative stress and inhibiting cell proliferation. Extracts of F. fomentarius have demonstrated strong antioxidant activity, with the DPPH radical-scavenging assay showing the highest potency, followed by β-carotene bleaching inhibition and ferric ion-reducing power, with EC₅₀ values of 114.40, 174.50, and 250.70 µg/mL, respectively.

Anti-inflammatory

Methyl 9-Oxo-(10E,12E)-octadecadienoate isolated from Fomes fomentarius attenuates lipopolysaccharide-induced inflammatory response by blocking phosphorylation of STAT3 in murine macrophages. Results from additional studies suggest that fomentariol differentially modulated inflammatory responses triggered by lipopolysaccharides in macrophages and is one of the bioactive compounds that mediate the physiological effects of Fomes fomentarius.

Antidiabetic

The antidiabetic activity of F. fomentarius is mainly achieved by inhibiting key enzymes such as α-glucosidase and DPP-4, regulating blood glucose metabolism, improving insulin secretion and insulin resistance, and thus reducing blood glucose levels. Fractionation of F. fomentarius extracts revealed fomentariol as a potent inhibitor of alpha-glucosidase and DPP-4, with higher activity against alpha-glucosidase than the reference drug acarbose; fomentariol presents a novel avenue for diabetes management, demonstrating simultaneous inhibition of key enzymes in glucose metabolism.

Anticancer / Antiproliferative

F. fomentarius ethanol extract (FFE) attenuated the expression of matrix metalloproteinase-9 and phosphorylation of Akt, as well as increased E-cadherin in MDA-MB-231 cells. FFE arrested the S and G2/M cell-cycle populations by inhibiting the expression of cell cycle regulatory proteins such as cyclin-dependent kinase 2, cyclin A/E, and S-phase kinase-associated protein 2. The polysaccharide MFKF-AP1β markedly inhibited A549 lung cancer cell growth in a dose-dependent manner based on the amount of lactate dehydrogenase (LDH) released and morphological alterations, and induced cellular apoptosis by causing single-stranded DNA breakage; MFKF-AP1β (25–100 µg/mL) significantly induced single-stranded DNA breakage in A549 cells, as shown by comet assay.

Neuroprotective (AChE Inhibition)

Studies have shown that bioactive compounds in F. fomentarius can reduce acetylcholinesterase (AChE) activity, suggesting its potential as a neuroprotective agent in conditions such as Alzheimer's disease.

5. Scientific Evidence by Area of Use

5.1 Wound Healing and Hemostasis

The strongest and most clinically grounded body of evidence for F. fomentarius concerns its use as a topical hemostatic and wound-care agent. This application dates continuously from prehistoric times through 19th-century European pharmacopeia practice. Fomes fomentarius was widely used throughout Europe as a styptic and as an absorbing wound bandage.

Clinical trials on patients with wounds, burns, and trophic ulcers indicated that topical application of the fibers resulted in stopping the bleeding, reducing pain, preventing inflammation and suppuration. These trials, associated with the research of Gorovoj and Burdukova (1996), represent some of the limited direct human clinical data available for F. fomentarius. According to in vitro, in vivo, ex vivo, as well as clinical studies, F. fomentarius fibers can modulate the immune system, contribute to intestinal health, accelerate wound healing, absorb heavy metals, organic dyes, and radionuclides, and normalize various physiological parameters. Evidence strength: Limited human clinical data exist; the most relevant human-applied evidence derives from the Ukrainian chitin fiber preparation Mycoton, studied in the mid-1990s to early 2000s. These reports lack the design rigor of modern randomized controlled trials and have not been independently replicated in high-quality contemporary studies.

5.2 Anticancer / Antiproliferative Activity

Multiple in vitro and animal studies have examined the antiproliferative and pro-apoptotic properties of F. fomentarius extracts and isolated compounds.

Fomes fomentarius is known to have anti-cancer, anti-inflammatory, and anti-diabetes effects; however, the underlying anti-cancer mechanism is not yet fully elucidated. To determine the molecular mechanism of the anti-cancer effects, various methods were used including fluorescence-activated cell sorting, Western blotting, migration, and crystal violet assays. FFE decreased cell viability in six cancer cell lines (MDA-MB-231, MCF-7, A549, H460, DU145, and PC-3).

In one study, the anti-tumor activity of a polysaccharide (MFKF-AP1β) isolated from fruiting bodies of Fomes fomentarius was analyzed in human lung cancer A549 cells. Selenium-enriched exopolysaccharide nanoparticles from F. fomentarius (SLN-EPS-Se) inhibited the growth of gastric cancer cells AGS and MKN45 by 70% and 60%, respectively, by inducing necrosis, apoptosis, and disruption in cell cycles after 3 days.

The fruiting bodies of Fomes fomentarius, an edible polypore mushroom, were historically utilized as drops or creams to halt bleeding and heal wounds. Esophageal, gastric, and uterine cancers have been reported to be treated with the fungus in traditional contexts.

Evidence strength: All anticancer evidence to date is preclinical — confined to in vitro cell-line studies and animal models. No human clinical trials assessing F. fomentarius against any cancer indication have been identified in peer-reviewed databases. The in vitro results, while mechanistically interesting (inhibition of AKT, cell cycle arrest, induction of apoptosis), cannot be extrapolated to clinical efficacy or safety in humans without further investigation.

5.3 Antidiabetic Activity

A water extract of F. fomentarius (100 mg/kg body weight) was orally administered once a day for 2 weeks in streptozotocin-induced diabetic rats; administering this water extract to STZ-induced diabetic rats lowered the serum glucose level by suppressing the increase in serum insulin level.

More recently, polysaccharide-based preparations have been examined: Oral administration of polysaccharide (PS), selenium-enriched PS (PS-Se), and their solid lipid nanoparticle formulations for 28 days to diabetic rats significantly declined blood glucose by 48.24%, 49.96%, 55.50%, and 60.47%, respectively; insulin secretion and body weight improved and HbA1c levels decreased; treatment alleviated lipid profiles, liver enzymes, and serum proteins; and histopathological observations of the liver, pancreas, and kidney confirmed antidiabetic impacts.

Ethanolic extracts exhibited superior inhibitory activity compared to water extracts, and further fractionation revealed fomentariol from Fomes fomentarius as a potent inhibitor of alpha-glucosidase and DPP-4, with higher activity against alpha-glucosidase than acarbose. However, comprehensive clinical studies are needed to evaluate its safety and efficacy in humans.

Evidence strength: Exclusively preclinical (in vitro enzyme inhibition and rodent models). No human trials have been conducted. Results from animal studies are promising but not translatable to clinical practice without further research.

5.4 Anti-inflammatory and Antinociceptive Activity

A key study by Park et al. (2004), published in Biological and Pharmaceutical Bulletin (volume 27, pages 1588–1593), examined the methanol extract of F. fomentarius for anti-inflammatory and anti-nociceptive effects. Studies demonstrated that extracts of F. fomentarius exerted antidiabetic, antioxidant, anti-inflammatory, antinociceptive, antibacterial, and cytotoxic activities.

Evidence strength: Preclinical (animal and in vitro). The anti-inflammatory mechanism via STAT3 phosphorylation blockade has been demonstrated in cell culture but not replicated in human studies.

5.5 Antimicrobial Activity

It has been reported that Fomes fomentarius effectively inhibited the growth of Staphylococcus aureus, Serratia marcescens, Bacillus subtilis, Pseudomonas aeruginosa, and Mycobacterium smegmatis.

In a study of Moroccan F. fomentarius, extracts exhibited broad-spectrum antimicrobial activity against all seven human pathogenic microorganisms tested, with Epidermophyton floccosum being the most susceptible (MIC = 2 mg/mL and minimal fungicidal concentration = 4 mg/mL) and Aspergillus fumigatus the most resistant (MIC = 26.67 mg/mL and MFC ≥ 64 mg/mL).

Scientists have shown potential therapeutic effects of Fomes fomentarius as it contains compounds that exhibit strong antiviral activity against human immunodeficiency virus (HIV)-1, and antimicrobial properties against the fungus Candida albicans and bacteria Helicobacter pylori.

Research has also identified that Fomes fomentarius inhibited the tobacco mosaic virus in experimental studies.

Evidence strength: All antimicrobial data are from in vitro studies. MIC values vary substantially between studies and strains. No clinical antimicrobial efficacy studies in humans exist.

5.6 Antioxidant Activity

A study assessing the safety and potential biological activities of extracts from Fomes fomentarius obtained through various ethanol concentrations (0%, 30%, 50%, 70%, and 100%) found that all extracts did not induce mutagenicity even up to 5 mg/plate concentration. In the assessment of antioxidant activity, only the hot water extract exhibited weaker antioxidant activity than the other ethanol extracts.

Evidence strength: In vitro antioxidant capacity is well-characterized across multiple extraction methods and assay types (DPPH, ABTS, FRAP, β-carotene bleaching). These are standard screening measurements and do not directly demonstrate antioxidant benefit in humans.

5.7 Neuroprotective (Anti-Acetylcholinesterase) Activity

Studies have shown that bioactive compounds from F. fomentarius can reduce AChE activity, making it a potential candidate for neuroprotective therapies in diseases like Alzheimer's disease.

Evidence strength: Early-stage preclinical. AChE-inhibitory activity has been demonstrated in cell-based assays. No human or animal intervention studies focused on neurodegenerative outcomes have been conducted with F. fomentarius.

5.8 Digestive / Gastrointestinal Applications

The Good Feeling Power® supplement, made from F. fomentarius fibers, has been investigated for its effect on colon health in cases of Crohn's disease, irritable bowel syndrome, and constipation, and may represent an attractive strategy to improve the life of patients suffering from gastro-intestinal complaints.

Based on the compatibility theory of traditional Chinese medicine and employing pharmaceutical preparation methods, researchers developed a Berberis-Fomes oral ulcer film using F. fomentarius fruiting bodies. This film exhibited remarkable curative effects on oral ulcers in rats, with a high healing rate, and possessed antibacterial, anti-inflammatory, and wound-healing-promoting functions.

Evidence strength: The gastrointestinal data are either case-report or rodent-level, or come from proprietary supplement literature without full peer-reviewed clinical trial reporting. Evidence for human benefit remains preliminary.

6. Body Systems and Health Areas

This mushroom is associated with a number of therapeutic properties such as antitumor, immunomodulatory, antioxidant, anti-inflammatory, hypocholesterolaemic, antihypertensive, antihyperglycaemic, antimicrobial, and antiviral activities. The specific body systems to which F. fomentarius research pertains include:

• Integumentary / Wound Care: Hemostasis, wound healing, burn management (topical chitin-glucan-melanin complex)
• Immune system: Immunomodulation via β-glucan polysaccharides; anti-infective properties
• Oncology (preclinical): Antiproliferative effects in lung, breast, prostate, and gastric cancer cell lines; modulation of PI3K/AKT/mTOR pathway
• Endocrine/Metabolic: Antidiabetic effects via α-glucosidase and DPP-4 inhibition; effects on lipid profile
• Gastrointestinal: Treatment of oral ulcers, gastroenteric disorders, hepatocirrhosis in traditional use; modern research into fiber-based supplementation for IBD
• Neurological (preclinical): AChE inhibition relevant to Alzheimer's disease models
• Cardiovascular/Metabolic: Hypocholesterolaemic and antihypertensive properties reported in reviews, though direct mechanistic studies are sparse
• Antimicrobial / Antiviral: In vitro activity against bacterial and fungal pathogens and HIV-1

7. Dosage Forms and Dosages Reported in Studies

No established pharmacopoeial dosage standards exist for Fomes fomentarius as a dietary supplement. The following dosages have been used specifically in the cited scientific studies:

• Animal antidiabetic study (Lee, 2005 — Nutrition Research): Water extract of F. fomentarius (100 mg/kg body weight) was orally administered once a day for 2 weeks in streptozotocin-induced diabetic rats.
• In vitro antiproliferative study (Kim et al., 2015 — Saudi Journal of Biological Sciences): The polysaccharide MFKF-AP1β was tested at concentrations of 25–100 µg/mL in A549 lung cancer cells.
• In vitro breast cancer study (PMC6429104): Concentrations of FFE at 0, 25, 50, and 100 µg/mL were treated on cancer cells in a 96-well format for 24 hours.
• Antioxidant characterization (Morocco study, 2025): EC₅₀ values for antioxidant activity were determined as 114.40, 174.50, and 250.70 µg/mL for DPPH, β-carotene bleaching, and ferric ion-reducing power assays, respectively.
• In vitro cytotoxicity: Dose-dependent FFE cytotoxicity with a half-maximal inhibitory concentration of 0.44 mg/mL was observed for L929 cells.
• Animal antidiabetic polysaccharide study: Oral administration of polysaccharide preparations for 28 days to diabetic rats resulted in significant declines in blood glucose (48.24%–60.47% depending on formulation).
• Antimutagenicity testing: All extracts did not induce mutagenicity even up to 5 mg/plate concentration in the Ames test.

8. Safety Considerations

Because of the tough anatomy and woody structure of the fruiting body, F. fomentarius is considered edible but non-palatable. The fruiting body is not described in the toxicological literature as poisonous.

In a systematic assessment of the safety and potential biological activities of extracts from Fomes fomentarius using various ethanol concentrations (0%, 30%, 50%, 70%, and 100%), all extracts did not induce mutagenicity even up to 5 mg/plate concentration. This suggests absence of mutagenic potential at tested concentrations in the Ames bacterial assay, though this does not constitute a comprehensive safety profile.

Despite its promising properties, F. fomentarius remains poorly explored, and many of its volatile and non-volatile constituents have yet to be fully identified and quantified, and their biological activities require further investigation.

Studies on Caco-2 intestinal cell lines found that polysaccharide (PS) and selenium-enriched polysaccharide (PS-Se) preparations had only minor toxicity.

Comprehensive clinical studies are needed to evaluate the safety and efficacy of F. fomentarius-derived compounds, including fomentariol, in humans. No formal human pharmacokinetic, pharmacodynamic, or toxicology studies have been published as of the sources reviewed.

There are no known documented drug interactions with F. fomentarius in the published peer-reviewed literature. Given its in vitro inhibition of α-glucosidase and DPP-4, theoretical caution is warranted regarding additive effects with antidiabetic medications, though this has not been studied in humans. Similarly, given in vitro AChE inhibitory activity, theoretical interactions with cholinesterase-inhibitor drugs merit acknowledgment pending clinical investigation.

The species is not covered under any established regulatory monograph (such as those of the German Commission E, ESCOP, or WHO) as of the sources surveyed, and there are no official dosage recommendations from any national or international health authority.

References

• ScienceDirect Topics: Fomes Fomentarius — overview (Food Bioscience, 2024)
• PMC12195499 — Bioactive Potential of Balkan Fomes fomentarius Strains: Novel Insights into Comparative Mycochemical Composition and Antioxidant, Anti-Acetylcholinesterase, and Antiproliferative Activities (2025)
• PMC12470752 — Bioactive Compounds and Pharmacological Properties of the Polypore Fomes fomentarius, a Medicinal Wild Mushroom Collected from Morocco (2025)
• PMC4487262 — Apoptotic Properties of Polysaccharide Isolated from Fruiting Bodies of Medicinal Mushroom Fomes fomentarius in Human Lung Carcinoma Cell Line (2015)
• PMC6429104 — Fomes fomentarius Ethanol Extract Exerts Inhibition of Cell Growth and Motility Induction of Apoptosis via Targeting AKT in Human Breast Cancer MDA-MB-231 Cells (2019)
• PMC5838475 — Isolation and Determination of Fomentariol: Novel Potential Antidiabetic Drug from Fungal Material (2018)
• ScienceDirect — Effects of Fomes fomentarius Supplementation on Antioxidant Enzyme Activities, Blood Glucose, and Lipid Profile in Streptozotocin-induced Diabetic Rats. Nutrition Research, 2005
• ScienceDirect — Fomes fomentarius: An Underexplored Mushroom as Source of Bioactive Compounds (Food Bioscience, 2024)
• MDPI — Fomentariol, a Fomes fomentarius Compound, Exhibits Anti-Diabetic Effects: An In Vitro Analysis (2024)
• MDPI — Evaluation of Antimutagenic and Antioxidant Properties in Fomes fomentarius L.: Potential Development as Functional Food (2024)
• Springer — Ethnomycological Use of Fomes fomentarius (L.) Fr. and Piptoporus betulinus in Transylvania, Romania. Genetic Resources and Crop Evolution (2016)
• SpringerLink — Fomes fomentarius (L.) Fr. – POLYPORACEAE (Book Chapter, 2023)
• ScienceDirect — Improving the Biological Properties of Fomes fomentarius Exopolysaccharide by Bioincorporating Selenium into Its Structure (2021)
• ResearchGate — Pharmacological Properties of Fomes fomentarius (2018)
• ResearchGate — Anti-Infective Properties of the Melanin-Glucan Complex Obtained from Fomes fomentarius (International Journal of Medicinal Mushrooms, 2011)
• ACG Publications — Chemical Constituents and Pharmacology of Fomes fomentarius: A Systematic Review (2025)
• EUREKA: Life Sciences — Evaluation of the Chitin-Glucan-Melanin Complex from Fomes fomentarius for Stopping Bleeding and Providing First Aid for Laceration and Burns in Combat Conditions (2024)
• ScienceDirect — Exploring the Therapeutic Properties of Chinese Mushrooms with a Focus on Their Anti-Cancer Effects: A Systemic Review (2024)
• NCBI Taxonomy — Fomes fomentarius (NIH/NLM)